Smoldering myeloma presenting as progressive multifocal leukoencephalopathy: a case report

Martina Troppmann1, Roland Büttner, Michael Boewer

  • 1Department of Internal Medicine I, University of Regensburg, Regensburg, Germany. martina.troppmann@klinik.uni-regensburg.de

Abstract

Insights

This case study shows progressive multifocal leukoencephalopathy (PML) reactivation due to John Cunningham virus (JCV) in an early plasmacytoma patient. Early diagnosis of PML is crucial for patients with atypical neurological symptoms or immunodeficiency.

Area of Science:

  • Neurology
  • Infectious Diseases
  • Oncology

Background:

  • Progressive multifocal leukoencephalopathy (PML) is an opportunistic infection linked to severe cellular immunodeficiency.
  • John Cunningham virus (JCV) reactivation can occur in immunocompromised individuals.
  • This case involves JCV reactivation in a patient with early-stage plasmacytoma.

Purpose of the Study:

  • To present a case of PML in a patient with early-stage plasmacytoma.
  • To highlight the role of cellular immunodeficiency in JCV reactivation.
  • To emphasize PML as a differential diagnosis in patients with neurological symptoms or immunodeficiency.

Main Methods:

  • A 76-year-old woman presented with hemiparesis and neurological deficits.
  • MRI revealed hyperattenuating lesions; PCR confirmed high JCV DNA levels in CSF.
  • Bone marrow biopsy diagnosed early-stage immunoglobulin G-kappa plasmacytoma.

Main Results:

  • Treatment with cidofovir led to significant improvement in neuropsychological symptoms.
  • Motor and sensory deficits showed no improvement.
  • The case demonstrated a rapid course of PML with severe residual deficits.

Conclusions:

  • PML should be considered in the differential diagnosis of patients with atypical neurological symptoms or immunodeficiency.
  • Cellular immunodeficiency plays a critical role in JCV reactivation.
  • Prompt diagnosis and management are essential for patients presenting with neurological decline and underlying immunodeficiency.